Top Story Today
The FDA Just Approved a Drug That Tricks Cancer Cells Into Eating Themselves
After 25 years of development, the FDA approved vepdegestrant (brand name Veppanu), the first-ever PROTAC drug, more than a month ahead of its deadline. Developed by Arvinas and Pfizer, the drug treats ESR1-mutated ER-positive breast cancer by hijacking a cell's own recycling machinery to destroy the disease-causing protein, rather than just blocking it. The pivotal trial showed it more than doubled progression-free survival versus the standard of care (5.0 vs. 2.1 months). Wall Street's enthusiasm is tempered by a narrow label; Jefferies had earlier cut peak sales forecasts to $434 million, far below the $3 to $5 billion some once imagined. But the real significance isn't commercial.
Why it matters: This approval validates targeted protein degradation as a viable clinical modality, giving a green light to dozens of PROTAC programs across oncology, neurology, and beyond. Every major drug class has to start with one awkward first product; antibodies did, and they're now a $270 billion market.
Read more →Clinical Trials and R&D
Moderna's Personalized Cancer Vaccine Keeps Getting Better at Three Years
The benefit isn't fading; it's deepening. Three-year data from Moderna and Merck's personalized mRNA melanoma vaccine showed a 49% reduction in cancer recurrence or death when paired with Keytruda, up from 44% at 18 months. The p-value tightened to 0.019, crossing into firmly significant territory. The phase 3 trial (roughly 1,100 patients) is now fully enrolled, with results expected in 2026.
Read more →Cancer's Favorite Weapon Just Got a Second Career in Autoimmune Disease
T-cell engagers were built to kill tumors. Cullinan Therapeutics just showed they can safely wipe out rogue B cells in lupus and RA patients too. Phase 1 data on CLN-978 demonstrated deep, dose-dependent B-cell depletion in both blood and tissue, though one Grade 3 CRS event at the highest dose level led to suspension of enrollment at that cohort. Over 40% of recent pharma multispecific deals now target autoimmune disease, and billions in deal-making ride on what comes next.
Read more →Regulatory and Policy
A Chinese Anesthetic Just Cracked the FDA for the First Time
Haisco Pharmaceutical's cipepofol became the first China-originated IV anesthetic to win FDA approval, extending the China-to-U.S. pipeline beyond oncology into mainstream hospital drugs. In trials, it matched propofol on efficacy while slashing injection-site pain from 77% to 18%. The FDA even waived the Phase II requirement, letting Haisco jump straight to a pivotal trial.
Read more →The FDA Told Gene Therapy Companies to Stop Reinventing the Wheel
New draft guidance lets genome-editing developers reuse manufacturing, safety, and clinical data across programs instead of rebuilding from scratch every time. A separate guidance lets certain oncology biologics skip traditional three-month animal studies. Both moves disproportionately benefit companies with mature, multi-asset platforms like Intellia and Beam Therapeutics.
Read more →The FDA Wants to Re-Study a Drug It Already Studied for 25 Years
Despite decades of clean post-marketing data, hundreds of peer-reviewed studies, and no new safety signals, the FDA is formally re-studying mifepristone's safety. Scientists say the review is driven by political and judicial pressure, not science. Over 260 researchers have denounced the paper that helped trigger it as methodologically flawed and never peer-reviewed.
Read more →Business and Markets
Roche Called U.S. Drug Pricing Tactics 'Cold-Blooded Blackmail'
Roche chairman Severin Schwan compared U.S. tariff-linked pricing negotiations to having a gun pointed at the company. Roche signed a deal in late 2025 to lower drug prices in exchange for a three-year tariff reprieve, but CEO Thomas Schinecker says the pressure has already killed some clinical trials and potential deals where the revenue math no longer works.
Read more →A $4 Semaglutide Syringe Just Launched in India
Alkem Laboratories launched a single-shot semaglutide syringe in India for roughly $4, while a month of Wegovy still costs $350 in the U.S. Over 40 Indian generic makers are now piling into the market after key patents expired. With 101 million diabetes patients in India, affordability was the only missing ingredient.
Read more →A Single Lawsuit Just Wiped Out Takeda's Entire Year of Profit
A Boston jury found Takeda liable in an antitrust case over a constipation drug called AMITIZA, awarding $885 million in damages that treble to roughly $2.5 billion under U.S. law. That single charge flipped Takeda's full fiscal year from a net profit of roughly $1.2 billion to a net loss of roughly $1 billion. Takeda plans to appeal.
Read more →The $787M Round Built to Survive a Geopolitical War
Earendil Labs closed $787 million in financing with an architecture designed to hedge U.S.-China tensions: Delaware incorporation, Beijing R&D, a potential Hong Kong IPO, and Sanofi as a strategic backer. The deal reflects a new reality where biotech capital formation must navigate rising geopolitical fragmentation across every major market.
Read more →